Physician profile
Diego A Diaz
NPI 1942270467
$21,008.98
in general payments reported to CMS, 2019-2025
48 companies · $3,770 in 2025
The $3,770 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,998 · 2020: $1,672 · 2021: $3,053 · 2022: $2,793 · 2023: $3,473 · 2024: $3,251 · 2025: $3,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $89.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,404.33 |
| Education | $89.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,657.99 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $3,581.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Janssen Pharmaceuticals, INC | $1,518.72 | 2019-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $1,408.07 | 2019-2025 | Dupixent |
| Insmed, INC. | $1,171.27 | 2019-2024 | Arikayce |
| Genzyme Corporation | $1,164.54 | 2019-2025 | |
| Philips North America LLC | $678.42 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pfizer INC. | $657.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.55 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Amgen INC. | $561.32 | 2019-2025 | Tezspire, Repatha |
| Grifols USA, LLC | $530.73 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $422.53 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $416.59 | 2019-2025 | Smartvest |
| Mylan Specialty L.P. | $366.22 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $340.74 | 2020-2025 | Glassia, Aralast |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.